Furthermore, although AD is also characterized by the accumulation of amyloid-β peptides, tau burden and not amyloid-β pathology has been shown to correlate with disease severity (Nelson et al., 2012), indicating that tau-targeting therapies may be valuable in ameliorating clinical progression. This evidence concerns the gene MAPT and Alzheimer disease.